Off-label use of atypical antipsychotics in personality disorders

Bibliography

• American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry 2001;158(10 Suppl):1-52
   Web of Science ®Google Scholar
• Zanarini MC. Psychotherapy of borderline personality disorder. Acta Psychiatr Scand 2009;120:373-7
   PubMed Web of Science ®Google Scholar
• Zanarini MC. Update on pharmacotherapy of borderline personality disorder. Curr Psychiatry Rep 2004;6:66-70
   PubMedGoogle Scholar
• Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs 2008;22:671-92
   PubMed Web of Science ®Google Scholar
• Buckley PF. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 2001;50:912-24
   PubMed Web of Science ®Google Scholar
• Lieb K, Vollm B, Rucker G, Pharmacotherapy for borderline personality disorder: cochrane systematic review of randomised trials. Br J Psychiatry 2010;196:4-12
   PubMed Web of Science ®Google Scholar
• Abraham PF, Calabrese JR. Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord 2008;111:21-30
   PubMed Web of Science ®Google Scholar
• Grilo CM, McGlashan TH. ‘Course and outcome’. In: Oldhan JM, Skodol AE, Bender D. editors. Essentials of personality disorders. VA American Psychiatric Press; Arlington: 2009. p. 63-85
   Google Scholar
• National Institute for Clinical Excellence (NICE). Borderline personality disorder: treatment and management. Clinical guideline. NICE; London: 2009
   Google Scholar
• Nose M, Cipriani A, Biancosino B, Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2006;21:345-53
   PubMed Web of Science ®Google Scholar
• Stoffers J, Vollm BA, Rucker G, Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 2010;6:CD005653
   PubMed Web of Science ®Google Scholar
• Bogenschutz MP, Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004;65:104-9
   PubMed Web of Science ®Google Scholar
• Linehan MM, McDavid JD, Brown MZ, Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008;69:999-1005
   PubMed Web of Science ®Google Scholar
• Schulz SC, Zanarini MC, Bateman A, Olanzapine for the treatment of borderline personality disorder: variable dose, 12-week, randomised doubleblind placebo-controlled study. Br J Psychiatry 2008;193:485-92
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001;62:849-54
   PubMed Web of Science ®Google Scholar
• Nickel MK, Muehlbacher M, Nickel C, Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006;163:833-8
   PubMed Web of Science ®Google Scholar
• Pascual JC, Soler J, Puigdemont D, Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry 2008;69:603-8
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004;65:903-7
   PubMed Web of Science ®Google Scholar
• Soler J, Pascual JC, Campins J, Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005;162:1221-4
   PubMed Web of Science ®Google Scholar
• Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2006;67:1042-6
   PubMed Web of Science ®Google Scholar
• Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry 2005;66:1298-303
   PubMed Web of Science ®Google Scholar
• Perrella C, Carrus D, Costa E, Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:158-63
   PubMed Web of Science ®Google Scholar
• Van den Eynde F, Senturk V, Naudts K, Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol 2008;28:147-55
   PubMed Web of Science ®Google Scholar
• Van den Eynde F, De Saedeleer S, Naudts K, Quetiapine treatment and improved cognitive functioning in borderline personality disorder. Hum Psychopharmacol 2009;24:646-9
   PubMed Web of Science ®Google Scholar
• Rocca P, Marchiaro L, Cocuzza E, Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002;63:241-4
   PubMed Web of Science ®Google Scholar
• Ilardi S, Craighead W. Personality pathology and response to somatic treatments for major depression: a critical review. Depression 1995;2:200-17
   Google Scholar
• Sanderson WC, Wetzler S, Beck AT, Prevalence of personality disorders in patients with major depression and dysthymia. Psychiatry Res 1992;42:93-9
   PubMed Web of Science ®Google Scholar
• Brieger P, Ehrt U, Marneros A. Frequency of comorbid personality disorders in bipolar and unipolar affective disorders. Compr Psychiatry 2003;44:28-34
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Frankenburg FR, Hennen J, Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. Am J Psychiatry 2004;161:2108-14
   PubMed Web of Science ®Google Scholar
• Fava M, Farabaugh AH, Sickinger AH, Personality disorders and depression. Psychol Med 2002;32:1049-57
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Russell JM, Delgado PL, Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry 1998;59:669-75
   PubMed Web of Science ®Google Scholar
• Mullen LS, Blanco C, Vaughan SC, Defense mechanisms and personality in depression. Depress Anxiety 1999;10:168-74
   PubMed Web of Science ®Google Scholar
• Skodol AE, Grilo CM, Keyes KM, Relationship of personality disorders to the course of major depressive disorder in a nationally representative sample. Am J Psychiatry 2011;168:257-64
   PubMed Web of Science ®Google Scholar
• Grilo CM, Stout RL, Markowitz JC, Personality disorders predict relapse after remission from an episode of major depressive disorder: a 6-year prospective study. J Clin Psychiatry 2010;71:1629-35
   PubMed Web of Science ®Google Scholar
• Schulz SC, Camlin KL, Berry SA, Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999;46:1429-35
   PubMed Web of Science ®Google Scholar
• Kool S, Dekker J, Duijsens IJ, Efficacy of combined therapy and pharmacotherapy for depressed patients with or without personality disorders. Harv Rev Psychiatry 2003;11:133-41
   PubMed Web of Science ®Google Scholar
• Newton-Howes G, Tyrer P. Pharmacotherapy for personality disorders. Expert Opin Pharmacother 2003;4:1643-9
   PubMed Web of Science ®Google Scholar
• Cardish RJ. Psychopharmacologic management of suicidality in personality disorders. Can J Psychiatry 2007;52(Suppl 1):115-27S
   Google Scholar
• Black DW, Blum N, Pfohl B, Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction, and prevention. J Personal Disord 2004;18:226-39
   PubMed Web of Science ®Google Scholar
• Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 2005;73:139-45
   PubMed Web of Science ®Google Scholar
• Agid O, Foussias G, Singh S, Where to position clozapine: re-examining the evidence. Can J Psychiatry 2010;55:677-84
   PubMed Web of Science ®Google Scholar
• Nielsen J, Dahm M, Lublin H, Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010;24:965-71
   PubMed Web of Science ®Google Scholar
• Benedetti F, Sforzini L, Colombo C, Low dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998;59:103-7
   PubMed Web of Science ®Google Scholar
• Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993;34:402-5
   PubMed Web of Science ®Google Scholar
• Oumaya M, Friedman S, Pham A, Borderline personality disorder, self-mutilation and suicide: literature review. Encephale 2008;34:452-8
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Ebeling T, Kang JS, Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 1999;60:477-84
   PubMed Web of Science ®Google Scholar
• Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 1998;52:13-19
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Tondo L. Lithium and suicidal risk. Bipolar Disord 2008;10:114-15
   PubMed Web of Science ®Google Scholar
• Khalifa N, Duggan C, Stoffers J, Pharmacological interventions for antisocial personality disorder. Cochrane Database Syst Rev 2010;8:CD007667
   Google Scholar
• Hirose S. Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psychiatry Clin Neurosci 2001;55:161-2
   PubMed Web of Science ®Google Scholar
• Alex R, Ferriter M, Jones H, Pharmacological interventions for obsessive-compulsive personality disorder (Protocol). Cochrane Database Syst Rev 2010;5:CD008517
   Google Scholar
• Farooq S, Vollm BA, Husain N, Pharmacological interventions for schizotypal personality disorder (Protocol). Cochrane Database Syst Rev 2011;3:CD009047
   Google Scholar
• Farooq S, Vollm BA, Stoffers J, Pharmacological interventions for schizoid personality disorder (Protocol). Cochrane Database Syst Rev 2011;3:CD009048
   Google Scholar
• Koenigsberg HW, Reynolds D, Goodman M, Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003;64:628-34
   PubMed Web of Science ®Google Scholar
• Skodol AE, Bender DS, Morey LC, Personality disorder types proposed for DSM-5. J Personal Disord 2011;25:136-69
   PubMed Web of Science ®Google Scholar
• Citrome L, Volavka J. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. Postgrad Med 2004;116:49-63
   PubMed Web of Science ®Google Scholar
• Aia PG, Revuelta GJ, Cloud LJ, Tardive dyskinesia. Curr Treat Options Neurol 2011;13:231-41
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93
   PubMed Web of Science ®Google Scholar
• Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007;21:911-36
   PubMed Web of Science ®Google Scholar
• Soloff PH, Meltzer CC, Becker C, Impulsivity and prefrontal hypometabolism in borderline personality disorder. Psychiatry Res 2003;123:153-63
   PubMed Web of Science ®Google Scholar
• Tost H, Alam T, Meyer-Lindenberg A. Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. Neurosci Biobehav Rev 2010;34:689-700
   PubMed Web of Science ®Google Scholar
• Gunderson JG. Pharmacotherapy for patients with borderline personality disorder. Arch Gen Psychiatry 1986;43:698-700
   PubMed Web of Science ®Google Scholar
• Links PS, Steiner M. Psychopharmacologic management of patients with borderline personality disorder. Can J Psychiatry 1988;33:355-9
   PubMed Web of Science ®Google Scholar
• Shafti SS, Shahveisi B. Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial. J Clin Psychopharmacol 2010;30:44-7
   PubMed Web of Science ®Google Scholar
• Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988;45:111-19
   PubMed Web of Science ®Google Scholar
• Goldberg SC, Schulz SC, Schulz PM, Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986;43:680-6
   PubMed Web of Science ®Google Scholar
• Leone N. Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry 1982;43:148-50
   PubMed Web of Science ®Google Scholar
• Ingenhoven T, Lafay P, Rinne T, Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry 2010;71:14-25
   PubMed Web of Science ®Google Scholar
• Mercer D, Douglass AB, Links PS. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. J Personal Disord 2009;23:156-74
   PubMed Web of Science ®Google Scholar
• Perugi G, Fornaro M, Akiskal HS. Are atypical depression, borderline personality disorder and bipolar II disorder overlapping manifestations of a common cyclothymic diathesis? World Psychiatry 2011;10:45-51
   PubMed Web of Science ®Google Scholar
• Philipsen A, Schmahl C, Lieb K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry 2004;37:196-9
   PubMed Web of Science ®Google Scholar
• Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry 1999;60:598-603
   PubMed Web of Science ®Google Scholar
• Philipsen A, Richter H, Schmahl C, Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry 2004;65:1414-19
   PubMed Web of Science ®Google Scholar
• Golubchik P, Sever J, Zalsman G, Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. Int Clin Psychopharmacol 2008;23:228-31
   PubMed Web of Science ®Google Scholar
• McClure MM, Barch DM, Romero MJ, The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biol Psychiatry 2007;61:1157-60
   PubMed Web of Science ®Google Scholar
• Gunderson JG, Weinberg I, Daversa MT, Descriptive and longitudinal observations on the relationship of borderline personality disorder and bipolar disorder. Am J Psychiatry 2006;163:1173-8
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Tondo L, Davis P, Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006;8:625-39
   PubMed Web of Science ®Google Scholar
• Alexander GC, Gallagher SA, Mascola A, Increasing off-label use of antipsychotic medications in the United States, 1995 – 2008. Pharmacoepidemiol Drug Saf 2011;20:177-84
   PubMed Web of Science ®Google Scholar